UA138190U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, folic acid, cartilaginous oligomeric matrix protein (COMP), C-reactive protein (SRP). With a homozygous carrier of 786-CC, levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of an opportunity to predict the dynamics of the process in the early subclinical stages, to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the nitric oxide synthase gene (eMmO5 17860), the content of thrombomodulin, folic acid, cartilage oligomeric matrix protein (COMP), C-reactive protein is determined in the patient's blood serum protein (SRP) and with homozygous carrier 786-

SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml, SRP "6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the EMO5 T786C gene polymorphism is determined, the content of thrombomodulin, folic acid, SOMP, SRP is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml, PSA 26 mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient Kh., 63 years old, was hospitalized in the clinic due to pain syndrome of the right hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of thrombomodulin, folic acid, SOMP, SRP were determined in the serum. A homozygous carrier of 786-SS was established, the levels of thrombomodulin - 12 ng/ml, folic acid - 2.6 ng/ml, SMP - 750 ng/ml, PSA - 16 mg/l.

The development of osteoarthritis was diagnosed. After 11 months, X-rays revealed phenomena

From osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (eMO5 17860), the content of thrombomodulin, folic acid, cartilage oligomeric matrix protein (COMP), C-reactive protein is additionally determined in the patient's blood serum protein (SRP) and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml, SRP "6 mg/l predict the development of osteoarthritis.